Drug Profile


Alternative Names: allo-APZ2-CVU; APZ2

Latest Information Update: 17 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator RHEACELL
  • Class Cell therapies; Skin disorder therapies; Stem cell therapies; Vascular disorder therapies
  • Mechanism of Action ATP-binding cassette transporter modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Varicose ulcer

Most Recent Events

  • 07 Aug 2017 RHEACELL GmbH initiates enrolment in a phase I/II trial for Varicose ulcer (In adults, In the elderly) in Germany (EudraCT2017-000233-31)
  • 29 Mar 2016 Phase-I/II clinical trials in Varicose ulcer (In adults, In the elderly) in Germany (Topical) (EudraCT2015-000399-81)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top